Event Details

Immatics Presenting at The 12th Annual Bioprocessing Summit (Virtual)

Join us on August 26^th for the 12^th Annual Bioprocessing Summit where Immatics will demonstrate how to utilize a target discovery platform, which identifies tumor targets and screens cognate TCRs for off target toxicities.  

E-meet Ali Mohamed for his presentation and engage in the following discussion about Immatics’ Manufacturing Platforms for Endogenous, Autologous, and Allogeneic TCR T Cell Therapies for Solid Cancers:

Wednesday, August 26, (12:55am EDT/ 5:55pm BST/ 6:55pm CEST)

Presentation: Manufacturing Platforms for Endogenous, Autologous, and Allogeneic TCR T Cell Therapies for Solid Cancers.  Ali Mohamed, PhD, Vice President, CMC, Immatics US, Inc. will present how Immatics utilizes XPRESIDENT® target discovery platform, which identifies tumor targets and screens cognate TCRs for off target toxicities and how these targets and TCRs are used in GMP manufacturing approaches for the various ACT product platforms. Exemplary manufacturing and/or clinical data from various trials will be presented for the various platforms.

Wednesday, August 26, (1:15am EDT/ 6:55pm BST/ 7:55pm CEST)

LIVE Q&A: Session Wrap-Up – an expert panel with Ali Mohamed, PhD, Vice President, CMC, Immatics US, Inc. as a member of the panel

We are looking forward to e-meeting you! 

Learn more about the Annual Bioprocessing Summit here https://www.bioprocessingsummit.com/